Valuation: Supernus Pharmaceuticals

Market Cap 1.64B 1.46B 1.35B 1.22B 2.29B 155B 2.35B 16.06B 6.46B 81.96B 6.15B 6.02B 260B P/E 2026 *
-188x
P/E 2027 * 14.7x
Enterprise Value 1.64B 1.46B 1.35B 1.22B 2.29B 155B 2.35B 16.06B 6.46B 81.96B 6.15B 6.02B 260B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.61x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.19%
1 week+2.34%
1 month-1.09%
3 months-8.87%
6 months-12.39%
Current year-15.65%
1 week 27.97
Extreme 27.97
44.31
1 month 27.97
Extreme 27.97
44.31
Current year 27.97
Extreme 27.97
59.68
1 year 27.97
Extreme 27.97
59.68
3 years 23.04
Extreme 23.045
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 65 2005-12-21
Director of Finance/CFO 68 2021-08-22
Compliance Officer 63 2011-12-31
Director TitleAgeSince
Director/Board Member 65 2005-12-21
Chairman 81 2016-08-09
Director/Board Member 80 2010-11-15
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Exercice

Chief Technology Officer

4,097 0.0073%
8/12/26 Exercice

Chief Financial Officer

3,104 0.0055%
8/12/26 Exercice

Founder

72,340 0.1290%

Financials

2026 *2027 *
Net sales 884M 790M 726M 659M 1.24B 83.78B 1.27B 8.66B 3.49B 44.22B 3.32B 3.25B 140B 1.02B 911M 837M 760M 1.43B 96.58B 1.46B 9.99B 4.02B 50.97B 3.83B 3.75B 162B
Net income -8.22M -7.34M -6.74M -6.12M -11.5M -778M -11.79M -80.47M -32.37M -411M -30.84M -30.18M -1.3B 113M 101M 92.5M 84.01M 158M 10.68B 162M 1.1B 444M 5.64B 423M 414M 17.86B
Net Debt - -
Projected Income Statement - Annual - Supernus Pharmaceuticals
Logo Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Sector
-
Date Price Change Volume
26-11-03 US$28.15 -32.85% 7,446,175
26-10-30 US$41.92 +0.19% 2,818,871
26-10-29 US$41.84 +1.85% 1,885,193
26-10-28 US$41.08 +0.29% 1,099,364
26-10-27 US$40.96 +0.47% 1,075,468
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Supernus Pharmaceuticals
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
28.15USD
Average target price
60.50USD
Spread / Average Target
+114.92%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Supernus Pharmaceuticals
  1. Stock Market
  2. Stocks
  3. SUPN Stock